9. SOME CLINICAL CHARACTERISTICS AND DEPRESSIVE DISORDERS IN MYASTHENIA GRAVIS PATIENTS AT MILITARY HOSPITAL 103

Nhu Dinh Son1, Nguyen Cong Tuyen2, Vu Thanh Cong2, Nguyen Trung Viet2, Nguyen Anh Quan2, Tran Le Quyen2
1 103 Military Hospital
2 Vietnam Military Medical University

Main Article Content

Abstract

Objective: To investigate the clinical characteristics and depressive disorders in patients with myasthenia gravis.


Subjects and Methods: A cross-sectional descriptive study was conducted on 83 myasthenia gravis patients treated at the 103 Military Hospital from July 2024 to March 2025.


Results: Most patients had an education level ranging from primary to secondary school (61.45%), and manual laborers accounted for a high proportion (57.83%). The mean age of disease onset was 45.2 years, with later onset in males compared to females. The average disease duration was 8.2 years, with 69.88% having the disease for over 4 years. The prevalence of depressive disorders was 45.78%, predominantly moderate in severity (68.42%). There was no significant association between depression and education level, occupation, or age of onset (p > 0.05). Depression severity increased with disease duration, with the highest prevalence in patients with disease duration over 4 years (p < 0.05).


Conclusion: Depressive disorders are common in patients with myasthenia gravis, with a positive correlation between disease duration and depression severity. Occupation, education level, and age of onset showed no clear impact on depression.

Article Details

References

[1]Andrade CP., Cruz MCN., Urrutia M., et al. (2010). Evaluation of depressive symptoms in patients with chronic renal failure, Rev Bras Psiquiatr, 28 (2): 168 – 172.
[2]Nadali J., Ghavampour N., Farzaneh Beiranvand, et al. (2022). Prevalence of depression and anxiety among myasthenia gravis (MG) patients: a systematic review and meta-analysis, J Psychosom Res, 37 (2): 63 – 69.
[3]Kulaksizoglu IB. (2007). Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment, CNS Drugs, 21 (6): 473 – 481.
[4]Shahrizaila N., Gengadharan PN., Goh KJ. (2024). Clinical characteristics and outcomes of generalized myasthenia gravis in Malaysia: a single-center experience, J Neurol Sci, 20 (4): 412 – 421.
[5]Singhal BS., Bhatia NS., Umesh T., et al. (2008). Myasthenia gravis: a study from India. Neurol India 56(3): 352–355.
[6]Mercante JP. (2005). Primary headaches in patients with generalized anxiety disorder, J Headache Pain, 12 (3): 331 – 338.
[7]Lipton RB, Natoli JL (2010). Global prevalence of chronic migraine: a systematic review, Cephalalgia, 30 (Supply 7): 1 – 96.